Author Index

The Journal of Immunology
Information for Authors

Go to www.jimmunol.org for the most up-to-date instructions.

Editorial Office E-mail: infoji@aai.org
Phone: 301-634-7197 Fax: 301-246-8401

ABOUT *THE JOURNAL OF IMMUNOLOGY*

Journal Facts:

- Publisher: *The Journal of Immunology* (*The JI*) is owned and published by The American Association of Immunologists, Inc. (AAI)
- Editor-in-Chief: Eugene M. Oltz, Ph.D., eic@aai.org
- Editorial Board: *The JI* Editorial Board is included in each issue. All editors are practicing scientists.
- Impact factor:
  Two-year: 4.539 (2017 Journal Citation Reports)
  Five-year: 4.99 (2017 Journal Citation Reports)
- Citations: *The JI* is cited more than any other immunology journal (2017 Journal Citation Reports)
- Number of research articles published/year: 670 (2018)
- Number of pages published/year: 7,796 (2018)
- Over 1.7 million page views per month (2018)
- Over 330,000 PDF downloads per month (2018)
- Publication schedule: Printed and posted online twice each month
- Issue dates: 1st and the 15th of each month
- Average time from submission to initial decision (full-length manuscripts): 30 days (2018)
- Average time from acceptance to publication ahead of print: 18 days (2018)
- Acceptance rate: 48% for full-length articles, 28% for Cutting Edge articles (2018)
- Online ISSN 1550-6606; Print ISSN 0022-1767

JOURNAL SCOPE AND CONTENT

***Full-Length Articles*:** *The JI* publishes peer-reviewed manuscripts describing novel findings in all areas of experimental immunology, including both basic and clinical studies. Articles are published in the following sections:

Allergy and Other Hypersensitivities
Antigen Recognition and Responses
Autoimmunity
Clinical and Human Immunology
Immune Regulation
Immune System Development
Immunogenetics
Immunotherapy and Vaccines
Infectious Disease and Host Response
Innate Immunity and Inflammation
Molecular and Structural Immunology
Mucosal Immunology
Systems Immunology
Transplantation
Tumor Immunology
Novel Immunological Methods

***Clinical and Human Immunology*:** Manuscripts submitted to the *Clinical and Human Immunology* section will be reviewed mindful of the limitations in sample size and depth of mechanistic analyses that may be inherent to these types of studies.

Novel Immunological Methods (see P. Fink. 2014. Introducing the *Novel Immunological Methods* section. *J. Immunol.* 192: 1339): Manuscripts submitted to the *Novel Immunological Methods* section should provide a new approach to important immunological problems. The manuscript should validate the technique, reagent, or genetically manipulated line of mice (and provide data on that) and indicate their utility for solving an immunologically interesting problem, but it is not necessary for the manuscript to solve that problem. The manuscript is evaluated on whether the technique, reagent, or line of mice is better than what is currently available and could therefore advance the field, as well as the usefulness of the technique, reagent, or line of mice to the field.

***Systems Immunology*:** Manuscripts submitted to the *Systems Immunology* section should center on analyses of novel large data sets, generated by the authors, which will serve as useful resources for future work in the field. The authors' informatics analyses should allow them to draw concrete conclusions, supported by the data, about the biology of the system(s) under study. Alternatively, manuscripts may describe a novel method of data analysis, which could be applied to publicly available data sets. The latter type of manuscript must convincingly demonstrate the utility of the new analysis method to reveal novel biological insights about the system(s) under study. However, it is not necessary for either type of manuscript to include definitive mechanistic analysis or experiments beyond those necessary for the acquisition of reproducible and meaningful data sets.

***Descriptions of New Reagents, Research Techniques, or Clinical Case Reports*:** These descriptions usually are appropriate only to the extent they provide innovative insight into unresolved problems or represent major breakthroughs.

As a point of reference, descriptions of the following would only be appropriate if they provide innovative insight into unresolved immunological problems, reveal novel structural features that are unique in an immunologically relevant manner, or represent major breakthroughs in the field:

- New reagents
- T cell or B cell epitopes
- Peptide binding motifs for previously uncharacterized MHC products
- Structures of MHC allelic products or MHC-peptide complexes not previously crystallized or homologs from previously uncharacterized species
- Three-dimensional structures of allergens or other antigens, antibody-defined epitopes, or antigen-antibody complexes

- Comparative analysis of proteins of immunological interest (intra- or inter-species comparisons)
- Research techniques
- Clinical case reports

Those wishing to report the identification of epitopes may do so at the Immune Epitope Database and Analysis Resource (http://www.immuneepitope.org/).

***Brief Reviews*:** *The JI* publishes a small number of invited reviews on a regular basis. These reviews are four to six journal pages in length, including illustrations and references. They cover a focused area on the advancing edge of immunology and provide a balanced view of current research that can be understood by researchers outside of that specialty. Authors interested in submitting a manuscript to *Brief Reviews* should submit a proposal, including an outline of the proposed review, by e-mail to the Editor-in-Chief at eic@aai.org.

***Cutting Edge Articles*:** *Cutting Edge* is the rapid publication section of *The JI*, presenting short reports describing significant advances in an area of immunology. Manuscripts submitted for consideration in this section should present scientifically sound and novel research in a clear and concise fashion and contain conclusions of unusual interest to immunologists that are justified from the data presented. Chief criteria for acceptance are scientific novelty and quality, originality, clarity, and conciseness. In addition to research articles, the *Cutting Edge* section publishes invited brief commentaries on controversial subjects of broad interest to immunologists.

***Immunology Notes and Resources*:** This is a feature where items of general interest to the immunology community may be published, such as articles on nomenclature or other significant items that may impact scientific research. These articles are published at the discretion of the Editor-in-Chief, who may seek advice from other editors or experts in the field. Submissions can be made by e-mail to the Editor-in-Chief at eic@aai.org.

***In This Issue*:** A small number of articles regarded by reviewers and editors as the top 10% in their field are highlighted in this section.

***Letters to the Editor*:** The Editor-in-Chief invites brief letters (250 words or less) of general interest, commenting on work published in *The JI* within the previous 3 months. A limited number of letters will be selected for publication. The authors of the original work will be invited to respond, and both the original letter and the authors' response will be published together. If you are interested in commenting on a published article, e-mail the Editor-in-Chief at eic@aai.org.

***Pillars of Immunology*:** In the first issue of each month, *The JI* reprints articles that have come to be regarded as classics in the field. An invited commentary accompanies each reprinted article, and a podcast is recorded of the commentary writer discussing the impact of the featured article on his or her own work and on the field in general. Podcasts can be found at http://www.jimmunol.org/ImmunoCasts. Suggestions for significant articles may be made by e-mail to the Editor-in-Chief at eic@aai.org. See the Pillars of Immunology page at http://www.jimmunol.org/pillarsofimmunology. *Pillars of Immunology commentaries represent the perspectives of their authors and are not meant to serve as definitive historical documents*. Suggestions for significant articles may be made by e-mail to the Editor-in-Chief at eic@aai.org.

***Translating Immunology*:** These invited articles highlight immunological discoveries that have led to a treatment, drug, or diagnostic device. See the Translating Immunology page at http://www.jimmunol.org/translatingimmunology.

COPYRIGHT TRANSFER

All manuscripts are considered to be the property of AAI from the time of submission. Should AAI not publish the manuscript, AAI releases its rights therein at the time the manuscript is returned to the corresponding author.

Articles published in *The JI* become the sole property of, with all rights in copyright reserved to, AAI.

The corresponding author, on behalf of all authors, signs a copyright transfer form. When all authors of a manuscript have written it as part of their official duties as employees of the U.S. government, the article is exempt from this requirement for transfer of copyright.

ARCHIVING IN PMC/EUROPE PMC

In March 2011, AAI began a new, free service to authors, to deposit selected manuscripts to PubMed Central (PMC). See also *Editorial Policies,* section on *NIH Public Access Policy.*

Several funding bodies, including the National Institutes of Health (NIH), Howard Hughes Medical Institute (HHMI), Wellcome Trust, and Medical Research Council (MRC-UK), mandate that authors deposit published articles into PMC or Europe PMC. While these mandates apply to authors, not publishers, the new AAI service will help authors comply with these mandates. On behalf of authors who are funded by NIH, HHMI, Wellcome Trust, and MRC-UK, AAI will deposit all manuscripts to NIHMS or Europe PMC, as applicable, that begin submission to *The JI* after 10 AM (EDT) March 29, 2011 and are ultimately accepted for publication; the author must select this option on the online submission form in order for AAI to do so. AAI will deposit the version of the manuscript that has undergone peer review and has been accepted for publication, before copy-editing and formatting.

Most funders mandate that articles be made available to the public in PMC at either 6 or 12 months after publication; manuscripts deposited by AAI will comply with these embargo periods. Authors will receive at least two e-mail notifications from PMC about their manuscripts. Authors must respond to both e-mails, in order for the process to be completed.

This free service is not applicable to work that is funded by bodies other than NIH, HHMI, Wellcome Trust, and MRC-UK. Authors funded by other entities that mandate deposition into PMC/Europe PMC must deposit the accepted version of the manuscript themselves.

How this service works:

- As part of the online submission process, authors select whether or not this service applies to them
- If the manuscript is accepted for publication, AAI will send all files, including Supplemental Data and video files, to NIHMS or Europe PMC for display in PMC or Europe PMC
- Authors will receive an e-mail from PMC (NIH/NLM/NCBI) or Europe PMC to approve the submitted files
- Authors will receive an e-mail from PMC (NIH/NLM/NCBI) or Europe PMC to approve the XML format
- After final approval by the author, PMC or Europe PMC will make the article publicly available after the embargo period

Further information is available at http://www.nihms.nih.gov/help/publishers.shtml.

MANUSCRIPT PREPARATION

See also *Scientific Publishing Dos and Don'ts for Authors and Reviewers* (http://aai.org/About/Publications/Additional/Docs/AAI_Dos_Donts.pdf).

***General Guidelines*:** A 12-point serif font, preferably Times New Roman, is required for all text, except within figures. Do not use compressed type format. Double-space the entire manuscript; number each line and each page. Each of the following components should begin on a separate page:

1. The **Title Page** must include the full title; a running title (not to exceed 60 characters); each author's full name as it should be published (first name, middle initial, last name); and the affiliations of all

authors and their institutions, departments, or organizations (use the following symbols in this order: *, †, ‡, §, ¶, ‖, #, **, ††, ‡‡, §§, ¶¶, ‖‖, ##). List the phone number, fax number, and e-mail address of the corresponding author on the title page. (See *Submit Online* for information about the corresponding author designation during submission and peer review.)

2. The **Abstract** must be 250 words or less for full-length manuscripts. Reference citations should not be included in the *Abstract*. The species of animals or species of origin of cells used in the manuscript must be clearly stated in the *Abstract.* Please ensure that the final few sentences (50 words or less) of the *Abstract* provide a succinct summary of the main point of the manuscript.

3. The **Introduction**, **Materials and Methods**, **Results,** and **Discussion** sections should begin on separate pages in that order. Do not combine the *Results* and *Discussion* sections for full-length manuscripts.

4. In either the **Materials and Methods** or in the figure legends, authors should include:

- The gating strategies used for flow cytometry experiments.
- Minimal Information About T cell Assays (MIATA), as appropriate.
- The original source for purchased or shared animals used to generate a colony, including the commercial vendor nomenclature that specifies the strain, if relevant.
- The number and gender of animals analyzed per experiment.
- The source of experimental and control animals, including whether they are littermates and/or cohoused.

5. **Acknowledgments** appear immediately after the *Discussion* and before *References*.

6. **Grant support** must NOT be included in the *Acknowledgments,* but should be cited as a footnote to the title. All funding sources must be disclosed and will be published as a footnote to the title; anonymous or pseudonymous funders are not permitted.

7. **References** must be numbered as they appear in the text and should refer to primary literature rather than review articles wherever possible. All authors must be listed for each reference. If citations are included in tables or in figure legends, they must be numbered according to the position of citation of the table or figure in the text. Only published articles and manuscripts in press may be included in the *References*. In press manuscripts, i.e., manuscripts not yet published, must be submitted as online attachments in PDF format at the time of manuscript submission. NOTE: Do NOT submit as attachment articles that are already published, e.g., manuscripts published ahead of print. Such manuscripts must be incorporated into the *References* and cited with their DOI numbers and year of publication. Citations of "manuscripts in preparation," "unpublished observations," "manuscripts posted on preprint servers," and "personal communications" must appear parenthetically in the text. Manuscripts "submitted for publication" (i.e., not yet accepted) must also be mentioned parenthetically in the text. Written approval by the persons cited in personal communications must accompany the manuscript unless they are also authors of the manuscript submitted to *The JI*.

Format for references:

Periodicals: Wells, A. D., M. C. Walsh, D. Sankaran, and L. A. Turka. 2000. T cell effector function and anergy avoidance are quantitatively linked to cell division. *J. Immunol.* 165: 2432–2443.

Books: McIntyre, T. M., and W. Strober. 1999. Gut-associated lymphoid tissue: regulation of IgA B-cell development. In *Mucosal Immunology*, 2nd Ed. P. L. Ogra, J. Mestecky, E. Lamm, W. Strober, J. Bienenstock, and J. R. McGhee, eds. Academic Press, San Diego, CA, p. 319–356.

Manuscripts published ahead of print: Fraser, D. A., A. K. Laust, E. L. Nelson, and A. J. Tenner. 2009. C1q differentially modulates phagocytosis and cytokine responses during ingestion of apoptotic cells by human monocytes, macrophages, and dendritic cells. *J. Immunol.* doi:10.4049/jimmunol.0902232.

8. **Chemical Structures:** Manuscripts describing new chemical compounds whose use is integral to the manuscript's conclusions must provide, either in the manuscript or through a publicly accessible web source, the chemical structure, synthesis and characterization of the compounds (including their purity) in enough experimental detail to allow other researchers to reproduce the synthesis and characterization.

9. **Footnotes** should be used to designate the source of support, new or special abbreviations used, correspondence address, current address, etc. *Footnotes* should be numbered consecutively and will appear on the title page, but for submission are grouped together and placed on a separate page between the *References* and the *Figure Legends*.

10. **Abbreviations** that may be used without definition are provided in the Standard Abbreviations list. Spell out nonstandard abbreviations used less than three times. Nonstandard abbreviations used three or more times must be defined in a footnote. Abbreviations and their definitions must be consistent throughout the text.

11. **Tables** must be numbered with Roman numerals in order of appearance in the text. All tables must have a title. Table legends are prepared as footnotes to the table and are included with the table. Tables must be in DOC file format. Each table should be submitted as a separate file.

12. **Figure legends** must be numbered with Arabic numerals in order of appearance in the text and should include a short title after the figure number. Where possible, symbols and patterns used to distinguish data should be defined in a key placed within the graphic rather than in the figure legend. All figure legends must specify the number of times each experiment was independently performed, as well as the number of animals or replicates in each experimental group. For flow cytometry experiments, authors should specify the gating strategies in the *Materials and Methods* or in the figure legend.

13. **Figures:** At initial submission, please submit low-resolution files of the smallest possible size that will convey the needed information. Smaller files can be downloaded more quickly by reviewers and will hasten the review process. Alternatively, a single PDF of text plus figures may be submitted at initial submission.

At submission of a revised manuscript, high-resolution figures that meet the following specifications must be submitted. For more information, see the GUIDELINES page on *The JI* Web site (http://www.jimmunol.org/sites/default/files/additional-assets/PDFs/TheJI_DigitalArtGuidelines.pdf) and TIPS page on the online manuscript submission home page (http://ji.msubmit.net).

- *Color*: Color figures must be in the RGB color space.
- *File Sizes*: Figures should not exceed 10 MB (average size is about 2 MB).
- *Image Sizes*: Figures should be submitted in final print publication size (printed 1:1). Figures may be published in print in one of three formats: 1-column wide (20 picas/3.3″/8.5 cm), 1.5-column wide (30 picas/5″/12.7 cm), or 2-column wide (41.5 picas/6.9″/18.5 cm). The single-column format is preferred. Unless the file size is too large, multi-panel figures should be submitted as a single file. Do not draw boxes around figures or figure parts.
- *Text and Lines*: Text within figures must be 6–8 points in size, except for single letter markers, which may be 12

points. Helvetica or Arial should be used for all figure text (except for the use of symbols). Line widths must be greater than one point thick or they will not be visible on the PDF version of the article.

- *Numbering*: Figures must be numbered to enable reviewers to know the figure number for each figure.
- *File Format*: Figures should be in **TIFF** (better for halftone art, e.g., blots and photographs), **EPS** (better for line art or monochrome art, i.e., anything that involves sharply delineated lines), or PDF format. PowerPoint files are not suitable quality, as their resolution is too low for print. Please see http://www.jimmunol.org/sites/default/files/additional-assets/PDFs/PPTtoTIFF_2017.pdf for detailed instructions on converting PowerPoint files to TIFF files.

14. **Digital Images:** All images submitted to *The JI* must accurately represent the original data. Original data (digital files, autoradiographs, films, etc.) for all experiments should be fully annotated, secured, and retrievable. The original image file (raw data file) should be kept in an unprocessed and noncompressed file format. For figures that are compiled into multi-figure panels, the individual image files should be kept. For additional information, see: http://jcb.rupress.org/content/166/1/11, http://jcb.rupress.org/content/172/1/9, and *Digital Images Dos and Don'ts* (http://www.jimmunol.org/sites/default/files/additional-assets/PDFs/DigitalImageDo-Dont.pdf).

Although manipulation of images should be kept to an absolute minimum, there are some circumstances when manipulations are necessary. If, however, the quality of an image is too poor to clearly convey the conclusion, the experiment should be repeated.

Figures in manuscripts considered for acceptance will be screened for evidence of inappropriate manipulation. Manuscript acceptance is contingent upon a satisfactory outcome of the screening process. Please adhere to the following guidelines in preparing figures for manuscripts:

- *Collecting Images*: If multiple images are compared to one another, collect each image in the same manner. Any post-collection processing should be applied in a uniform manner to all images. If differences in collection/postcollection are necessary, these need to be described in the legend or the *Materials and Methods* section.
- *Brightness and Contrast*: Adjustments in brightness and contrast should be avoided if possible. If the brightness or contrast of an image needs minor adjustment, the adjustments must not obscure or eliminate any information and must be applied to the entire image. Significant adjustments should not be made. Do not use excessive contrast that removes background. Always note any adjustment in the legend or in the *Materials and Methods* section.
- *Cloning Tools*: Images should not be "airbrushed" (with Clone Stamp Tool/Clone Brush) to remove "blemishes." Do not use cloning tools to insert something into an image from elsewhere.
- *Gels/Blots*: All gels should contain a positive and a negative control, and a set of molecular weight markers. For Western blots, control panels (actin, GAPDH, etc.) should come from a stripped and reprobed membrane of the experimental blot shown. If this is not possible, the control blots should be derived from the same samples, and this should be indicated in the figure legend.
- *Cropping*: Conservative cropping of gels and blots to improve clarity and conciseness may be permitted if the following points are observed:
  - important bands must be retained
  - at least several band widths should be retained above and below the cropped band
  - cropping must be noted in the legend
  - band(s) of interest must be clearly labeled
  - molecular weight marker positions should be shown in all gels/blots
- *Splicing*: Occasionally, images are spliced to rearrange the order of samples for the sake of presentation, such as those in a Western blot. If splicing of data from a single experiment is necessary, draw contrasting (black or white) vertical lines to indicate where the images were joined and state the manipulation in the legend. It would be preferable to rerun the gel so the order is correct. Images from different experiments should not be spliced to form a new single image.

***Cover Art*:** Cover art is selected from images in accepted manuscripts and changes with each issue of *The JI*. Authors are encouraged to submit color figures with their manuscripts for possible use as cover illustrations. If an image is selected as cover art, the file must have a resolution of at least 300 dpi at a size of $8.5'' \times 11''$.

***Estimating Manuscript Length*:** One printed page in *The JI* contains approximately 8,000 characters, including spaces. Thus, an eight-page, full-length article would contain approximately 64,000 characters. Each line in a table occupies about 60 characters for a single-column table (120 characters for a double-column table). Figures occupy about 180 characters per centimeter height for single-column figures (360 characters for double-column figures). Determine the total character count for the text of your manuscript, and add the character-equivalents for the tables and figures. This will provide a reasonable estimate for the printed length of an article.

***Web Links in Submitted Manuscripts*:** Links to Web sites are permitted only if the information contained on the Web site is not essential to the understanding and assessment of the manuscript or to the ability to repeat the experiments described in the manuscript. Web links will not be checked after submission for correctness or functionality; it is the responsibility of the author to ensure that the Web link is correct.

***Human and Animal Use*:** All studies involving human subjects must be conducted in accordance with the guidelines of the World Medical Association's Declaration of Helsinki (most recent revision). All animal studies must be performed in compliance with the U.S. Department of Health and Human Services Guide for the Care and Use of Laboratory Animals (or otherwise equivalent guidelines). A statement that human and/or animal studies have been reviewed and approved by an appropriate institutional review committee must be included in the *Materials and Methods* section of the manuscript.

DEPOSITING IN PUBLIC DATABASES

***High-resolution structural data*:** Any manuscript submitted to *The JI* that contains new high-resolution structural data requires an accession number from the Protein Data Bank (PDB) (http://www.rcsb.org/pdb) and assurance that unrestricted release will occur at or before the time of publication. The accession number should be accompanied by the Web site address of the databank.

For studies containing x-ray protein structures, authors must also submit the PDB Summary Validation Report (http://www.wwpdb.org/validation/validation-reports) (provided after annotation by the wwPDB [http://www.wwpdb.org/]) for review at the time of submission.

***Nucleotide sequences*:** Sequences of nucleotides or amino acids longer than 50 bases/residues should not be presented in the text or in table form, but rather should be submitted as a publication quality figure. Original nucleotide sequences, determined nucleotide

sequences encoding reported amino acid sequences, and files of nucleotide sequences derived from high throughput/deep sequencing (RNA-seq, ChIP-seq, MeDIP-seq, etc.) described in the manuscript must be submitted to the appropriate public database (e.g., GenBank [http://www.ncbi.nlm.nih.gov/Genbank/] or the European Nucleotide Archive [http://www.ebi.ac.uk/ena]) at the time of manuscript submission. Trace and short read sequencing data should be deposited at the NCBI Trace Archives (http://www.ncbi.nlm.nih.gov/Traces/home/), NCBI SRA (http://www.ncbi.nlm.nih.gov/sra) or ENA's Sequence Read Archive (http://www.ebi.ac.uk/ena/submit/read-submission). An accession number and sequence availability are required at the time of publication. The accession number should be accompanied by the Web site address of the databank.

***Microarray data*:** *The JI* will not publish descriptive manuscripts that report microarray data, unless such information can be considered of unusual immunological significance and/or include functional experiments that provide novel insight into mechanism. As with other scientific approaches, current experimental, quantitation, verification, and statistical analyses are expected. Microarray experiments should be Minimum Information About a Microarray Experiment (MIAME) compliant (for guidelines, see http://fged.org/projects/miame/). Whereas limited online space may be available for supplemental tables associated with the manuscript, complete microarray data must be deposited in the appropriate public database (e.g., GEO [http://www.ncbi.nlm.nih.gov/geo/] or ArrayExpress [http://www.ebi.ac.uk/arrayexpress/]), and must be accessible without restriction from the date of publication. An entry name or accession number must be included in the manuscript before publication. The accession number should be accompanied by the Web site address of the databank.

STYLE GUIDE

General style conventions: In general, *The JI* follows *Scientific Style and Format: The CSE Manual for Authors, Editors, and Publishers, 7th Edition*, published by the Council of Science Editors, Inc., in instances where style issues are not directly addressed.

***Abbreviations for references*:** PubMed (http://www.ncbi.nlm.nih.gov/journals) is the primary source for journal name abbreviations.

***Nomenclature*:** The most current links for nomenclature guidelines are posted online.

Allergen nomenclature: The systematic allergen nomenclature of the World Health Organization/International Union of Immunological Societies (WHO/IUIS) Allergen Nomenclature Sub-Committee should be used for manuscripts that include the description or use of allergenic proteins. For manuscripts describing new allergen(s), the systematic name of the allergen must be approved by the WHO/IUIS Allergen Nomenclature Sub-Committee prior to manuscript publication. To avoid the risk of delay of publication, authors are encouraged to apply for a new allergen name using the posted submission form at the WHO/IUIS Allergen Nomenclature Web site (http://www.allergen.org/) before manuscript submission. The systematic nomenclature consists of the first three letters of the taxonomic genus of the allergen source, followed by a space; the first letter of the species epithet, followed by a space; and an Arabic numeral usually indicate the chronological order in which the allergen was described. For example, the first allergen to be purified from the house dust mite *Dermatophagoides pteronyssinus* is named "Der p 1". Further examples of the systematic allergen nomenclature for over 500 allergens can be found at the WHO/IUIS Allergen Nomenclature Web site. The submissions to the Allergen Nomenclature Sub-Committee will be kept confidential until publication if requested by the authors.

CD nomenclature: For the purpose of consistency, *The JI* will follow CD nomenclature. For murine molecules, *The JI* will follow the nomenclature previously published (*J. Immunol.* 160: 3861–3868, 1998). For human molecules, standard CD nomenclature will be followed as updated (*J. Immunol.* 168: 2083–2086, 2002). See also http://www.hcdm.org/.

Chemical names: Follow the *IUPAC-IUB Commission on Biochemical Nomenclature-Chemical Abstracts* (http://www.chem.qmul.ac.uk/iupac/bibliog/white.html) or the *Chemical Abstracts Guide to Naming and Indexing of Chemical Substances* for proper spelling and style of chemical names.

Chemokine/chemokine receptor nomenclature: The systematic name for chemokines and chemokine receptors should be used. The original name may be given in parentheses if desired. See *Cytokine* 21: 48–49, 2003.

Enzyme nomenclature: Enzyme Nomenclature (http://www.chem.qmul.ac.uk/iubmb/enzyme/) is *The JI* source for style and spelling of enzyme names.

Gene nomenclature for humans: The HUGO guidelines (http://www.genenames.org/) for gene symbols and nomenclature should be used for naming human genes; nomenclature of genome sequence variants should use the Human Genome Variation Society (HGVS) (http://www.hgvs.org/) nomenclature, summarized at http://varnomen.hgvs.org/. If commonly found in the literature, alternative nomenclature may be used in addition to HGVS nomenclature. Authors should submit all variants included in a manuscript to the relevant database (e.g., dbVar [http://www.ncbi.nlm.nih.gov/dbvar/content/submission/]) for public release if the manuscript is published; the accession number and database URL should be included in the manuscript.

Gene and strain nomenclature for mice: Mouse Genome Informatics (http://www.informatics.jax.org/) is a reference source for naming mouse genes. A current listing of inbred strains of mice and rats is also available at Mouse Genome Informatics (http://www.informatics.jax.org/mgihome/nomen/strains.shtml). Authors are also encouraged to deposit their mapping data with the Mouse Genome Database (MGD) before publication and to include the assigned MGD accession numbers in their manuscripts. Information about electronic submission of datasets can be obtained at the Data and Nomenclature Submissions page (http://www.informatics.jax.org/submit.shtml). Gene symbols should be reserved with MGD in advance of publication.

HLA nomenclature: HLA nomenclature is updated periodically by the World Health Organization Nomenclature Committee for Factors of the HLA System. Annual comprehensive revisions are published in *Human Immunology*. See also EMBL-EBI (http://www.ebi.ac.uk/ipd/imgt/hla/).

SUPPLEMENTAL DATA

- Supporting data that are not essential to understanding the material presented in the manuscript may be submitted with the original manuscript for peer review; however, the print version of the article must stand on its own without the supplemental material.
- Supplemental material is primarily intended for short videos, large tables, large sequence alignments, or large data sets. Additional supplemental figures and tables that support the interpretation and conclusions drawn in the manuscript may, however, also be submitted for review with the manuscript.
- Supplemental material must be submitted as separate files from the rest of the manuscript during the online submission; select "Supplemental Data" as the "File Type" when uploading the files.

- Apart from videos, all files must be either PDF or Excel file format; multiple PDF files should be combined into a single PDF file.
- For Cutting Edge manuscripts, no more than four supplemental figures and/or tables may be submitted. One of the allowable Cutting Edge supplemental items can be a description, no more than one page in length, of computational or bioinformatics methods. Methods that are normally found in the body of the manuscript may not be included in this Cutting Edge supplemental item.
- For full-length manuscripts, no more than four supplemental figures and/or tables may be submitted. An exception to this limit can be made for manuscripts submitted to the Systems Immunology category.
- Each supplemental figure should comprise no more than a single 8.5″ × 11″ PDF page and be large enough to be legible when that page is opened.
- Legends or short explanations must accompany all supplemental figures and videos; no other supplementary text is permitted in full-length manuscripts. Legends should be placed below the corresponding figure in the PDF. Legends for videos should be submitted as a single PDF. Table legends must be prepared as footnotes to the table; all tables must have a title.

*Note: Excel files will be converted to PDFs for the review process only. At publication, the file(s) will be uploaded in the original Excel format.

Videos must be 320 × 480 pixels or smaller for best viewing within a browser. Videos must be no longer than 30 seconds and under 10 MB, with no sound or voice-over. Submit videos in MPG or QuickTime format. Change QuickTime file extensions to ".mov" so that Web browsers will recognize the file type and play the movie. Compress videos as much as possible to help control file size. Name videos by order of citation appearance (e.g., video1.mov). Select "Video" as the "File Type" when uploading the files during online submission. Authors will be notified if problems exist with videos as submitted and will be asked to take responsibility for modifications. No editing will be done to videos at the Editorial Office. A legend or short explanation must accompany the video.

Supplemental figures and tables related to a published article in *The JI* will be available in a PDF and appended to the manuscript online. All citations of the supplemental material in the online version are linked in the full-text HTML and PDF for convenient access. In the printed article, supplemental material will be footnoted with the following text: "The online version of this article contains supplemental material."

Supplemental materials are posted online as provided by the author. There is a publication charge of $75 per supplemental figure or table.

CUTTING EDGE MANUSCRIPT PREPARATION

Manuscripts submitted to the *Cutting Edge* section should conform to the *General Guidelines* for full-length manuscripts, as well as the additional guidelines below:

1. *Cutting Edge* articles, including figures and references, ***must fit within five journal pages.*** Authors should estimate the size of figures and tables and limit the text accordingly. One printed page in *The JI* contains approximately 8,000 characters, including spaces. Thus, a 5-page *Cutting Edge* article would contain approximately 40,000 characters. The formula for estimating the number of pages is provided in *Manuscript Preparation*.
2. The *Abstract* is limited to 150 words.
3. The *Materials and Methods* section may be sharply limited, but should be sufficient to allow the evaluation of results and conclusions.
4. Authors may combine the *Results* and *Discussion* sections.

PREPARATION OF THE REVISED MANUSCRIPT

Follow *The JI* Editorial Office instructions contained in the previous decision letter carefully and thoroughly. A revised manuscript not returned within 9 months of the date of the decision letter will be considered a new manuscript and subject to a new, complete review.

Individual manuscript files, files for each figure and table (even if they are unchanged from the previous submission), and a point-by-point reply to all referee comments must be uploaded to the system. The revised manuscript text must be marked to show changes using yellow highlighting (Microsoft Word files preferred). Do not show deletions displayed by tracked changes because if the manuscript is accepted, this version will be immediately sent for publication. High-resolution figure files must be submitted. Figures must be in **TIFF**, **EPS**, or **PDF** format and prepared as described under *Figures*. Authors should retain for themselves copies of all the files in their original formats.

Key Points (required): Authors submitting revised manuscripts are required to supply two or three single-sentence key points that summarize their findings. Each key point must be no more than 85 characters, including spaces. The key points should be located on the same page with the *Abstract* and listed below the *Abstract* in its own section.

Visual Abstracts (optional): Authors submitting revised manuscripts also are given the option to submit a visual abstract, which is a captionless figure that summarizes their findings. Unfortunately, *The JI* does not offer design assistance. The file specifications are as follows:

- PDF, EPS, JPG, or TIFF format
- 300 dpi minimum image resolution
- 440 pixels wide and 350 to 365 pixels tall. The width cannot exceed 440 pixels, or the image will not display properly in the article view.

There is no charge for visual abstracts.

SUBMIT ONLINE

Submit online at ji.msubmit.net.

1. For the initial submission of **full-length manuscripts**:
   - A format-neutral manuscript may be submitted for the first round of review. Manuscripts do not need to be formatted according to *The JI* guidelines for the initial submission, except that all authors must be listed for each reference. NOTE: Numbering of lines and pages, and easy-to-read figures will make the task of the reviewers and editors easier.
   - Either a PDF of the entire manuscript (text, figures, and tables), or individual manuscript, figure, and table files may be uploaded to the system. If individual files are uploaded, the system then creates a single PDF for review purposes.
2. For **Cutting Edge submissions** and all **revised manuscripts**:
   - Individual manuscript, high resolution figure, and table files must be uploaded to the system. Authors should save copies for themselves of all the files in their original formats.
3. See *Author Instructions* (https://ji.msubmit.net/cgi-bin/main.plex?form_type=display_auth_instructions) for online submission requirements.
4. See *Manuscript Preparation*, sections on *Figures* and *Digital Images* for help with preparing digital art.

5. *The JI's* online submission system requires browsers where cookies and Javascript are enabled.
6. The system will ask submitters to designate the Corresponding Author.
7. Authors will be offered the option to include their ORCID number.
   - Corresponding Authors may utilize this option during submission.
   - Contributing Authors should update their "Profile" (at bottom of the home screen, under "General Tasks") with their ORCID number. Then, during submission, the "Find Person" button should be used to enter the Contributing Author (enter "Last Name," then click "Find Person," and select the correct person from the drop down menu); this will pull in the ORCID for the Contributing Author.
   - If authors wish to include their ORCID numbers, these must be submitted via the submission system; they CANNOT be added or corrected at proof stage.

***Who Can be a Corresponding Author?*:** The Corresponding Author must be the person who has the authority to take responsibility for all obligations related to the manuscript and its submission. These responsibilities include but are not limited to:

1. Ensuring the scientific integrity of the submission;
2. Confirming that all authors have read and concur with the submission of the manuscript;
3. Resolving any authorship disputes;
4. Ensuring that all funding sources are listed in a footnote to the title;
5. Making unique materials available to qualified investigators;
6. Complying with requirements to deposit microarray and other similar datasets in public venues;
7. Confirming that any human and/or animal studies have been approved by an appropriate institutional review committee;
8. Ensuring that all conflicts of interest or financial interests are listed;
9. Confirming that the manuscript is original;
10. Confirming that no part of the manuscript has been previously published, submitted elsewhere, or posted on the Internet;
11. Ensuring that the manuscript contains no fabrications, fraud, or plagiarism;
12. Transferring the copyright interest in the manuscript and all Supplemental Materials to AAI;
13. Maintaining/archiving all data related to the manuscript;
14. Signing the Submission form and the Publication Charges forms.

Someone other than the Corresponding Author may begin online submission of the manuscript (this person can upload the files and enter all required information). However, the Submission and Publication Charges forms MUST be completed by the Corresponding Author. If the Submitter is not the Corresponding Author, the submission will move from the Submitter's account to the Corresponding Author's account when the Submitter has completed all parts of the submission except the forms, to enable the Corresponding Author to complete the forms.

Please note that the Corresponding Author is the person who receives and responds to communication from the Editor-in-Chief and Editorial Office during the peer-review process. The designation of Corresponding Author does not refer to the person with whom readers may correspond after an article is published.

After the manuscript has been checked by journal staff, the Corresponding Author will receive an e-mail acknowledging receipt of the manuscript. Please contact infoji@aai.org if you do not receive the acknowledgment e-mail.

PUBLICATION FEES

Submission fees are waived and certain publication fees are reduced for Corresponding Authors who are Regular, Associate, Emeritus, or Honorary AAI members in good standing at the time of submission and manuscript acceptance, respectively. To review membership qualifications or to join AAI now, visit https://www.aai.org/membership.

All publication fees are payable in U.S. dollars. Accepted manuscripts are published only upon commitment by the author(s) or institutional financial officer to pay these charges.

Submission Fee*:** If the Corresponding Author is not an **AAI member, a nonrefundable fee of $50 per manuscript must be paid by credit card (American Express, MasterCard, or Visa) during the submission process. If payment by credit card is impossible, please contact infoji@aai.org to arrange payment by check (drawn on a U.S. bank). We do not accept cash or purchase orders.

*There is no submission fee for Corresponding Authors who are Regular, Associate, Emeritus, or Honorary AAI members in good standing.

Page Charges:

- $70 per page for up to 8 printed pages in the article
- $175 for each additional page from 9 to 12 pages
- $225 for each additional page over 12 pages

***Color Charges*:** Color figures may include multiple color panels. Within 24 hours of receiving page proofs, authors will be notified of the estimated cost of color reproduction via a link in an e-mail from aubilling.djs@sheridan.com. Authors must confirm acceptance of the charges in writing. Authors should expect that color figures in the accepted manuscript will be reproduced in color and will incur color charges.

Note that AAI members receive a significant discount on color charges:

- Non-AAI Members: $600 for each color figure.
- AAI Members: $300 for each color figure for Corresponding Authors who are Regular, Associate, Emeritus, or Honorary AAI members in good standing on the date of manuscript acceptance.

***Supplemental Material*:**

- $75 per supplemental figure or table.

***Online Posting Fee*:** $150 per published article.

***Reprints*:** Reprints must be ordered in advance of publication. Within 24 hours of receiving page proofs, authors will receive an e-mail directing them to the author billing system. From this site, you will be able to order reprints, view the estimated charges for your upcoming article, and make payments electronically. Reprint orders from noncontributors must be directed to the Editorial Office.

THE JI AUTHOR CHOICE OPTION

Authors who wish to make their article freely available immediately upon publication in *The JI* may utilize the *Author Choice* option.

NOTE: Some funders require that the Creative Commons Attribution License (CC BY) be used whenever their funds are used to pay an Open Access fee. These authors must use the "CC BY Author Choice Submission Form" form under "Electronic Forms" during the submission process. The "CC BY Author Choice Submission Form" is for use ONLY by authors whose funders require CC BY and who ALSO select the Author Choice option.

NOTE: The AAI meets the Wellcome Trust Publisher Requirements (https://wellcome.ac.uk/funding/managing-grant/publisher-requirements).

The AAI, as standard policy, makes all content in *The JI* available to the public at no cost 12 months after publication (*The JI Online*).

The *Author Choice* option is available for $2,500 to Corresponding Authors who are Regular, Associate Emeritus, or Honorary AAI members at the time of manuscript acceptance. The Author Choice fee for Corresponding Authors who are not members of AAI is $3,000. The Author Choice fee is in addition to other Publication Fees (such as page charges, color charges, and Supplemental Data charges).

Authors may select the *Author Choice* option during resubmission of manuscripts that have been returned for revision; the option is not offered at the first round of review. If the manuscript is accepted on the first round of review, authors will be offered the *Author Choice* option via e-mail before files are sent for copyediting. The *Author Choice* fee will be included in the invoice for Publication Fees.

If the Corresponding Author decides against the Author Choice option after selecting it during submission, s/he must notify infoji@aai.org prior to returning page proofs; once page proofs have been returned, the Author Choice fee will be charged and cannot be reimbursed.

In addition to being made freely available on *The JI* Web site immediately upon publication, AAI will deposit the published version of *Author Choice* articles into PMC for immediate posting there as well as on the PMC mirror sites (Europe PMC and PMC Canada).

***Reuse Terms and Conditions*:** For articles published under the CC BY 4.0 license, see https://creativecommons.org/licenses/by/4.0/.

The American Association of Immunologists, Inc. ("AAI") makes the *Author Choice* articles (collectively, the "Articles") available under the terms and conditions below. By accessing and using the Articles you agree to the following:

1. You may, solely for noncommercial purposes, access, download, copy, distribute, and display the Articles, and create derivative works from the Articles, subject to the following restrictions:

a. You do not affect the authors' moral rights to the Articles in any way;

b. If a third party owns any part of any Article, you are responsible for obtaining permission from the copyright owner to use that portion of the Article;

c. If you use an Article for noncommercial research or educational purposes, you must include the appropriate bibliographic citation (authors, journal, article title, volume, issue, page numbers, DOI, and the link to the definitive published version on www.jimmunol.org);

d. Copyright notices and other disclaimers may not be removed from any Article;

e. Any translation of any Article must include, in a prominent manner, the statement: "This is an unofficial translation of the article that appeared in *The Journal of Immunology*. The American Association of Immunologists, Inc. has not approved this translation"; and

f. Any adaptations of any Article must include, in a prominent manner, the statement: "This is an unofficial adaptation of the article that appeared in *The Journal of Immunology*. The American Association of Immunologists, Inc. has not approved this adaptation."

2. Use of the Articles for any commercial purpose is prohibited.

3. The definitive published version of each Article resides on *The JI* Web site, located at www.jimmunol.org. *AAI makes the Articles available as-is, and makes no representations or warranties, express or implied, regarding the Articles. In no event shall AAI be liable for any loss or damage arising out of or in connection with the use of, or any information in, any Article.*

For permissions other than those listed above, or for articles not published as Author Choice, go to http://www.aai.org/About/Publications/JI/copyright.html.

PEER REVIEW INFORMATION

***The Process*:** By submitting a manuscript to *The JI*, the authors agree to subject it to the confidential peer-review process. Editors and reviewers are informed that the manuscript must be considered confidential. After a manuscript is received, it is assigned by the Ph.D. scientists on staff to a specific Deputy Editor and a Section Editor whose expertise is considered to be appropriate. The Section Editor prepares a list of expert reviewers, which may include some suggested by the staff Ph.D. scientists. Authors can indicate specific individuals whom they would like to have excluded as reviewers. Generally, requests to exclude certain potential reviewers will be honored except in fields with a limited number of experts.

All potential reviewers are contacted individually to determine availability. Manuscript files are sent to at least two expert reviewers. Reviewers are asked to complete the review of the manuscript within 2 weeks and to return a short review form. Based on the reviewers' comments, the Section Editor recommends a course of action and communicates the reviews and recommendations to the Deputy Editor for a final decision.

The Deputy Editor considers the comments made by the reviewers and the recommendation of the Section Editor, selects those comments to be shared with the authors, makes a final decision concerning the manuscript, and prepares the decision letter for signature by the Editor-in-Chief. If revisions of the manuscript are suggested, the Deputy Editor also recommends who should review the revised manuscript when resubmitted. Authors are informed of the decision by e-mail; appropriate comments from reviewers and editors are appended.

***Decisions*:** There are four categories for initial decisions: accept, accept with minor revision, return for revision, and reject. Some manuscripts are accepted provisionally, pending relatively minor revisions. In this case, the Deputy Editor may conduct the rereview. For many manuscripts, authors are invited to resubmit if revision or additional experimentation can address major criticisms. Typically, one or more reviewers will then be asked to consider the adequacy of the revisions. *Cutting Edge* manuscripts are allowed only minor revisions because of time constraints. All revised manuscripts are carefully reexamined, and ultimate acceptability is not guaranteed. *The JI* does not provide for an advance determination of the acceptability of a particular manuscript for publication, nor does it promise expedited review of selected manuscripts.

***Communication with Authors*:** To minimize the possibility of misinterpretation or errors in verbal communication, the Editorial Office will provide information, in writing, only to the corresponding author and will not provide extensive details (e.g., exact status of a review or a predicted time to final decision). Deputy Editors do not take calls from authors concerning decisions or other related matters. All such inquiries should be addressed in writing to the Editor-in-Chief, who will discuss concerns with the Deputy Editor. This policy has been established to provide uniformity and fairness when addressing concerns about the review process.

***Manuscripts Submitted from the Institution of an Editor*:** Manuscripts submitted from the institution of any Section or Deputy Editor or the Editor-in-Chief are reviewed by other editors from outside that institution. The Editorial Office ensures confidentiality and equity in reviewing all manuscripts.

***Rebuttals*:** If the authors believe that a serious scientific error occurred during the review, a letter of rebuttal may be sent to the Editor-in-Chief explaining the reasons why the decision should be reconsidered. Letters of rebuttal must be received by the Editor-in- Chief within 6 weeks of the date the decision letter was sent. When appropriate, the matter will be taken up with the initial Deputy Editor, Section

Editor, or additional reviewers. Rebuttals that challenge rejections that were based on priority alone are rarely successful, since the assignment of priority is necessarily a matter of opinion. If the authors of a rejected manuscript are able to make new advances that go far beyond the original submission, they will often expedite consideration of their manuscript through the submission of a completely new manuscript.

REVIEWERS

***Selection*:** Selection of reviewers is the responsibility of the Section Editor, although the Ph.D. scientists on staff make recommendations to the Section Editor from a database of individuals who have reviewed manuscripts previously. This database includes self-identified areas of expertise, as well as information about the perceived usefulness and timeliness of past reviews. Individuals who consistently have provided tardy or unhelpful reviews are removed from the database. Every effort is made to avoid both real and apparent conflicts of interest with respect to research activities or collaborative or personal interactions. Reviewers are asked to withdraw from considering any manuscript in which they identify a conflict that has escaped the attention of the Section Editor.

***Scientific Integrity*:** Information contained in manuscripts is considered confidential and should not be shared or distributed. If necessary, a reviewer can consult with others for an adequate evaluation of the research findings if all individuals involved maintain confidentiality, objectivity, and avoid conflict of interest. AAI is not responsible for acts and conduct by reviewers that are not in accordance with accepted professional standards. Reviewers are asked to be objective in their evaluations and to judge primarily the novelty and soundness of the information presented.

***Anonymity*:** Although reviews are anonymous, all comments should be capable of withstanding public scrutiny. Except in very unusual circumstances, the identity of the reviewers and Section and Deputy Editors involved in the review of any given manuscript is kept confidential.

TRANSFER OPTION

With the launch of its open access journal *ImmunoHorizons*, AAI now offers authors the option to transfer a manuscript submitted to *The JI* to *ImmunoHorizons*. This option will be offered when the editors consider that the manuscript submitted to *The JI* does not meet the requirements of *The JI* but may be suitable for *ImmunoHorizons*. The offer will be made in the decision letter after review of a manuscript submitted to *The JI*. If the author chooses to transfer the manuscript via the link provided in the decision letter, all files and reviews will be transferred to *ImmunoHorizons* for rapid evaluation by the *ImmunoHorizons* editors. Authors may also contact *The JI* office (infoji@aai.org) to request transfer of previously reviewed and rejected manuscripts.

THE JI EDITORIAL BOARD

The AAI Council, upon recommendation of the Publications Committee, appoints the Editor-in-Chief for a term of 5 years. Deputy Editors, Section Editors, and Associate Editors (http://www.jimmunol.org/EditorialBoard) are nominated by the Editor-in-Chief and appointed by the Publications Committee. The Editor-in-Chief, the Deputy Editors, and the Section Editors constitute the Editorial Board. Deputy Editors are appointed for variable terms. Section Editors and Associate Editors are appointed for one renewable term of 2 years in most circumstances. Deputy Editors, Section Editors, and Associate Editors are required to be members of AAI. The Editor-in-Chief is responsible for the specific editorial conduct of *The JI*. The AAI Publications Committee is responsible for the management and evaluation of *The JI* and any other official publications of AAI, subject to the general supervision of the AAI Council.

EDITORIAL POLICIES

***Scientific Misconduct*:** AAI will evaluate the credibility of all allegations of scientific misconduct, e.g., suspected fabrication or falsification of data, double publication, or plagiarism. If the Editor-in-Chief determines that an allegation has merit, s/he will first attempt to address the matter with the Corresponding Author. Should that fail to resolve the situation satisfactorily, the Editor-in-Chief will contact the institution of the Corresponding Author to request an investigation; the Editor-in-Chief may also contact the coauthors and/or the funder(s) of the published research.

Until the matter is clarified, no additional submissions by any author of the disputed manuscript or published article will be considered for publication. If scientific misconduct is confirmed by the institution, and no request for retraction is made either by the institution or by any author, the Editor-in-Chief will report his/her findings to a representative of the AAI Publications Committee, and in consultation with a representative of the AAI Council, will decide appropriate action.

Only the Corresponding Author, coauthors, and appropriate representative(s) of the relevant institution(s) will be apprised of the status of, or any action(s) taken in response to, allegations of scientific misconduct.

***Retain Original Data*:** Authors are expected to retain the original, raw data presented in a published article for the length of time required by the authors' funding source or institution; if the institution or funding source does not have a data retention policy, then data should be kept for at least 6 years after publication of the article in which it is presented (as per HHS guidelines [http://ori.hhs.gov/sites/default/files/42_cfr_parts_50_and_93_2005.pdf]). AAI reserves the right to alter this time limit in extenuating circumstances.

***Embargo Policy*:** For manuscripts considered to be in press or approved for publication, the public release of information should not precede the actual publication of the work. The publication date is defined as the date the first copy is mailed from the printer or the first day the article is posted online. Please note that the issue date and mail dates do not necessarily coincide. This embargo policy protects the peer-review process and the newsworthiness of the scientific content of published articles, and minimizes the chance for the appearance of misinformation in the lay press. The policy also ensures that scientists have access to all relevant information at the same time as the public. These restrictions do not apply to the presentation of the work at scientific conferences or symposia that precede the actual publication date. Although news reporters may be present at such meetings or symposia, information, tables, or illustrations that in any way duplicate the content of a manuscript submitted for publication or in press should not be provided to reporters by the authors. In particular, press conferences should not be held before the embargo date. The official release of videotape presentations and electronic prepublication of articles on the Internet should adhere to the embargo policy. Violations of these policies are legitimate grounds for withdrawal of the article from publication or other measures that AAI may choose to take.

***Conflict of Interest Disclosures*:** All funding sources must be disclosed in a footnote to the title; anonymous or pseudonymous funders are not permitted.

Any potential conflict of interest in a submitted manuscript must be disclosed in the "Conflict of Interest" section of the online submission system.

Authors of submitted manuscripts that contain information affecting actual or potential commercial products must declare any conflict of interest or financial interest in the product or in potentially competing products held by them, their spouses, or their minor children. Financial interests include consultancies, employment, service on Board of Directors, honoraria, royalties, research support, grants, or contracts, if any exceed $5,000 per year in any of the preceding 5 years. They also include expert testimony, or patents received or pending, stock, and equity interests (diversified mutual funds or investment trusts do not constitute competing financial interests). The conflict should be stated briefly on the online manuscript submission screen (e.g., "J.B. Doe has received royalty payments from PQR Incorporated."). It is the responsibility of the Corresponding Author to review this policy with all authors and to list collectively the relevant relationships.

All disclosures will remain confidential during the review process, but manuscripts accepted for publication will acknowledge conflict of interest and financial interests in a published disclaimer describing the nature of the interests. If authors declare no conflict of interest or financial interests, this also will be noted in a published disclaimer.

***Image Manipulation*:** Figures in manuscripts considered for acceptance will be screened for evidence of manipulation. Manuscript acceptance is contingent upon a satisfactory outcome of the screening process. As a result of screening, authors may be asked to supply the original (raw) data upon which the figures were based. Inability to supply the original data may result in rejection of the manuscript. If the editors deem that the manipulation has affected the interpretation of the data, the manuscript will be rejected for publication. Cases of suspected misconduct may be referred to the institution of the Corresponding Author; the Editor-in-Chief may also contact the coauthors and/or the funder(s) of the research. Please see *Manuscript Preparation*, section on *Digital Images* for more information.

***NIH Public Access Policy*:** As of April 7, 2008, the U.S. National Institutes of Health (NIH) requires that manuscripts accepted for publication and that describe research funded in whole or in part with NIH funds be deposited into the NIH PMC repository. Other funding bodies also mandate deposition into PMC.

AAI views this policy as a costly, duplicative effort that diverts federal dollars from biomedical research. For more information about how publishing in *The JI* relates to the policy, please see the Funding Body Public Access Policy: Frequently Asked Questions (http://www.jimmunol.org/info/PublicAccessFAQ).

Despite AAI's serious concerns about these policies, AAI has undertaken to help authors comply with them. On behalf of authors who are funded by NIH, AAI will deposit all articles to PMC that begin submission to *The JI* after 10 AM (EDT) March 29, 2011, and are ultimately accepted for publication; the author must select this option on the online submission form in order for AAI to do so. AAI will deposit the version of the manuscript that has undergone peer review and has been accepted for publication, before copyediting and formatting.

NIH mandates that articles be made available to the public in PMC at 12 months after publication; manuscripts deposited by AAI will comply with this embargo period. Authors will receive at least two e-mail notifications from PMC about their manuscripts. Authors must respond to both e-mails in order for the process to be completed.

In addition to NIH, a number of additional funding agencies also mandate submission to PMC/Europe PMC. AAI will also deposit on behalf of authors funded by HHMI, Wellcome Trust, and MRC-UK; for details, see *Archiving in PMC/Europe PMC*.

This free service is not applicable to work that is funded by bodies other than NIH, HHMI, Wellcome Trust, and MRC-UK. Authors funded by other entities that mandate deposition into PMC/Europe PMC must deposit the accepted version of the manuscript themselves.

Authors agree not to deposit the manuscript to any other repository (except a thesis repository if required), agency, or entity.

***Other Funding Agencies*:** Authors funded by other entities that mandate deposition into PMC/Europe PMC must deposit the accepted version of the manuscript themselves. Authors funded by agencies that mandate submission to PMC with public access within 6 months after publication must sign the 6 month-PMC Submission Form during the online submission process.

***Prior Publication*:** Submission of a manuscript to *The JI* implies that the content has not been published previously and will not be submitted for publication elsewhere while the manuscript is under review. *The JI* considers research results (excluding abstracts and student dissertations) to have already been published if they are publicly available with a fixed content (i.e., content is in an unalterable form) and are citable in any language.

Previous publication of a particular figure may not prevent subsequent publication in *The JI* if that figure is essential to the submitted manuscript and does not constitute the major contribution. Previously published portions of a manuscript must be accompanied by a permission release from the copyright holder and must be cited.

Preprints, whether paper copies or postings on a publicly accessible Web site, are not considered publications, nor are poster presentations of work at a conference. Authors who post to a preprint site must retain copyright of the work. Authors who post to a preprint site should identify the preprint server and include the accession number or DOI in their cover letter. Manuscripts posted to the bioRxiv preprint server (http://biorxiv.org/) can be directly transferred to *The JI* for peer review, without the need to reupload files or re-enter information at *The JI* submission site. To transfer a preprint, click the "Submit preprint to a journal" link on your bioRxiv page, and select "*The Journal of Immunology*" from the dropdown menu. If *The JI* publishes the manuscript, authors should request the preprint server to acknowledge publication and cite the journal reference (including the DOI to link to the published article).

An invited manuscript published in a non–peer-reviewed journal, however, would be considered a prior publication.

Submissions of previously published research, as defined by the criteria, must contain a disclosure statement; it is at the Editor-in-Chief's discretion whether to allow peer review of the work in these instances.

***Unique materials*:** It is required that unique materials developed for manuscripts published in *The JI* that are not available from commercial suppliers will be made available, within reason, to qualified investigators for their own noncommercial use. An agreement to this effect is included in the Manuscript Submission Form. A reasonable amount may be charged by authors to cover preparation and shipping of the requested material.

Any restrictions on sharing of materials (for example, Material Transfer Agreements or patents) that apply to unique materials developed for the manuscript must be disclosed in the *Materials and Methods* section of the manuscript.

STANDARD ABBREVIATIONS

The abbreviations listed here are used without definition in articles published in *The JI*. The form may be used for both singular and plural, or made plural with "s" at the author's option.

Å, angstrom
aa, amino acid (only with numbers)
Ab, antibody
ABTS, 2,2′-azinobis(3-ethylbenzthiazoline-6-sulfonic acid)

ADP, adenosine 5′-diphosphate
Ag, antigen
AIDS, acquired immunodeficiency syndrome
AMP, adenosine 5′-monophosphate
ANOVA, analysis of variance
AP-1, activator protein 1
APC, Ag-presenting cell
ATP, adenosine triphosphate
BALB/c, a mouse strain
BALT, bronchus-associated lymphoid tissue
BAPTA-AM, 1,2-bis(2-aminophenoxy)ethane-*N*,*N*,*N*′,*N*′-tetraacetic acid acetoxymethyl ester
BCR, B cell receptor
bp, base pair (only with numbers)
BrdU, 5-bromo-2′-deoxyuridine
BSA, bovine serum albumin
C, complement
C region, constant region of Ig
cAMP, cyclic AMP
C terminus, carboxyl terminus
C-terminal, carboxyl-terminal
CCL, CC chemokine ligand
CCR, CC chemokine receptor
CD40L, CD40 ligand
cDNA, complementary DNA
CDP, cytidine 5′-diphosphate
CDR, complementarity determining region
C/EBP, CCAAT/enhancer-binding protein
CFA, complete Freund's adjuvant
CFSE, 5-(and 6-)-carboxyfluorescein diacetate succinimidyl ester
CFU, colony-forming unit
cGMP, guanosine 3′,5′-cyclic monophosphate
CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate
Ci, curie
CIITA, class II transactivator
CLIP, class II-associated invariant-chain peptide
cM, centiMorgan(s)
CMP, cytidine 5′-monophosphate
CMV, cytomegalovirus
CNS, central nervous system
CoA, coenzyme A
Con A, concanavalin A
CpG, cytosine guanine dinucleotide
cpm, counts per minute
CREB, cAMP response binding protein
cRNA, complementary RNA
CSF, colony-stimulating factor
CTL, cytotoxic T lymphocyte
CTLA, cytolytic T lymphocyte-associated Ag
CTP, cytidine 5′-triphosphate
CXCL, CXC chemokine ligand
CXCR, CXC chemokine receptor
d, day(s) (only with numbers); deoxy; distilled (as in dH2O)
D region, diversity region of Ig or T cell receptor for Ag
Da, dalton (only with numbers)
DAPI, 4′,6′-diamidino-2-phenylindole
DEAE, diethylaminoethyl
df, degrees of freedom
DMEM, Dulbecco's modified Eagle's medium
DMSO, dimethylsulfoxide
DNA, deoxyribonucleic acid
DNase, deoxyribonuclease
DNP, dinitrophenyl
dpm, disintegrations per minute
ds, double-stranded (as dsDNA)
DTT, dithiothreitol
E, erythrocyte
EBV, Epstein-Barr virus
EC_{50}, 50% effective concentration
ECL, enhanced chemiluminescence
ED_{50}, 50% effective dose
EDTA, ethylenediaminetetraacetic acid
EGTA, ethylene glycol-bis(β-aminoethyl ester)-*N*,*N*,*N*′,*N*′-tetraacetic acid
ELISA, enzyme-linked immunosorbent assay
ELISPOT, enzyme-linked immunospot
EMSA, electrophoretic mobility shift assay
ERK, extracellular signal-regulated kinase
E:T ratio, effector to target ratio
Fab, Ag-binding fragment
F(ab′)2, two Fab units linked by disulfide bridges between fragments of the heavy chain
F-actin, filamentous actin
FACS, fluorescence-activated cell sorting
FAM, 6-carboxyfluorescein
FBS, fetal bovine serum
FcR, Fc receptors (e.g., FcγRI)
FCS, fetal calf serum
FITC, fluorescein isothiocyanate
FLICE, Fas-associated death domain-like IL-1β-converting enzyme
FLIP, FLICE inhibitory protein
FLT3, *fms*-related tyrosine kinase 3
fMLF, formyl-methionyl-leucyl-phenylalanine
fura 2-AM, fura 2-acetoxymethyl ester
g, gram (only with numbers)
GALT, gut-associated lymphoid tissue
GAPDH or G3PDH, glyceraldehyde-3-phosphate dehydrogenase
G-CSF, granulocyte CSF
GDP, guanosine 5′-diphosphate
GFP, green fluorescent protein
GM-CSF, granulocyte-macrophage CSF
GMP, guanosine 5′-monophosphate
gp, glycoprotein (e.g., gp100)
GPI, glycosylphosphatidylinositol
GST, glutathione *S*-transferase
GTP, guanosine 5′-triphosphate
h, hour (only with numbers)
H chain, heavy chain
H&E, hematoxylin and eosin
HBSS, Hanks' balanced salt solution
HEPES, *N*-2-hydroxyethylpiperazine-*N*′-2-ethanesulfonic acid
HIV, human immunodeficiency virus
HLA, human histocompatibility leukocyte Ag
HPLC, high performance liquid chromatography
HRP, horseradish peroxidase
HSV, herpes simplex virus
HUVEC, human umbilical vein endothelial cell
IC_{50}, 50% inhibition/inhibitory concentration
ICAM, intercellular adhesion molecule
ICOS, inducible costimulator
Id, idiotype; idiotypic determinant
ID_{50}, 50% infective dose or 50% inhibiting dose

IDO, indoleamine 2,3-dioxygenase
IFA, incomplete Freund's adjuvant
IFN, interferon (e.g., IFN-γ)
Ig, immunoglobulin
IgH, Ig heavy chain
IκB or I-κB, inhibitory NF-κB
IL, interleukin (e.g., IL-2)
i.m., intramuscular
IMDM, Iscove's modified Dulbecco's medium
IMEM, Iscove's minimal essential medium
i.p., intraperitoneal
ITAM, immunoreceptor tyrosine-based activation motif
ITIM, immunoreceptor tyrosine-based inhibitory motif
IU, international unit
i.v., intravenous
J region, joining region of Ig or T cell receptor for Ag
JAK or Jak, Janus kinase
JNK, c-Jun N-terminal kinase
kb, kilobase (only with numbers)
kbp, kilobase pair (only with numbers)
K_a, association constant
K_d, distribution coefficient; dissociation constant
K_D, affinity constant
kDa, kilodalton (only with numbers)
L chain, light chain
LD_{50}, 50% lethal dose
LFA, leukocyte (lymphocyte) function-associated Ag
LIF, leukemia inhibitory factor
LPS, lipopolysaccharide
LU, lytic unit
2-ME, 2-mercaptoethanol
mAb, monoclonal Ab
2-ME, 2-mercaptoethanol
MACS, magnetic-activated cell sorting
MALDI, matrix-assisted laser desorption ionization
MALDI-TOF, matrix-assisted laser desorption ionization-time of flight
MALT, mucosa-associated lymphoid tissue
MAPK, mitogen-activated protein kinase
MCP, monocyte chemoattractant protein
M-CSF, macrophage CSF
2-ME, 2-mercaptoethanol
MEK, mitogen-activated protein kinase kinase
MEM, minimum essential medium
MES, 2-(*N*-morpholino)ethanesulfonic acid
mg, milligram (only with numbers)
MHC, major histocompatibility complex
min, minute (only with numbers)
MIP, macrophage-inflammatory protein
ml, milliliter (only with numbers)
MLC, mixed lymphocyte culture
MLR, mixed leukocyte reaction
mo, month(s) (only with numbers)
MOPS, 4-morpholinepropanesulfonic acid
M_r, relative molecular mass
mRNA, messenger RNA
MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-dimethyltetrazolium bromide
μg, microgram (only with numbers)
μl, microliter (only with numbers)
m.w., molecular weight
MyD88, myeloid differentiating factor 88
n, number in study or group
NAD, nicotinamide adenine dinucleotide
NADH, reduced NAD
$NaDodSO_4$, sodium dodecyl sulfate
NADP, NAD phosphate
NADPH, reduced NAD phosphate
NBT, nitroblue tetrazolium
ND, not determined
NDP, nucleoside 5′-diphosphate
NF, nuclear factor
NFAT or NF-AT, nuclear factor of activated T cells
NF-κB, nuclear factor κB
Ni-NTA, nickel-nitrilotriacetic acid
NK cell, natural killer cell
NMP, nucleoside 5′-monophosphate
NO, nitric oxide
NOD, nonobese diabetic
NS, not significant
nt, nucleotide (only with numbers)
N-terminal, NH2-terminal or amino-terminal
N terminus, NH2 terminus or amino terminus
NTP, nucleoside 5′-triphosphate
OCT, octamer-binding factor
OD, optical density
OVA, ovalbumin
p, probability
PAGE, polyacrylamide gel electrophoresis
PBL, peripheral blood lymphocyte
PBMC, peripheral blood mononuclear cell
PBS, phosphate-buffered saline
PCR, polymerase chain reaction
PE, phycoerythrin
PECAM-1, platelet endothelial cell adhesion molecule-1
PerCP, peridinin chlorophyll protein
PFU, plaque-forming unit
PG, prostaglandin
PHA, phytohemagglutinin
PI3K, phosphatidylinositol 3-kinase
PIPES, piperazine-*N*,*N*′-bis(2-ethane sulfonic acid)
PMA, phorbol myristate acetate
PMSF, phenylmethylsulfonyl fluoride
PWM, pokeweed mitogen
r, recombinant (e.g., rIFN-γ)
R, receptor (e.g., IL-2R)
RACE, rapid amplification of cDNA end
RAG, recombination-activating gene
RANTES, regulated upon activation, normal T cell expressed and secreted
RBC, red blood cell
RFLP, restriction fragment length polymorphism
RIA, radioimmunoassay
RNA, ribonucleic acid
RNase, ribonuclease
rpm, revolutions per minute
RPMI, (usually RPMI 1640)
rRNA, ribosomal RNA
RT-PCR, reverse transcriptase polymerase chain reaction
s, second (use only with numbers)
s.c., subcutaneous
SCID, severe combined immunodeficiency
SD, standard deviation
SDS, sodium dodecyl sulfate
SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis
SE, standard error
SEM, standard error of the mean

SHIP, src homology 2-containing inositol 5′-phosphatase
SIV, simian immunodeficiency virus
sp. act., specific activity
ss, single-stranded (e.g., ssDNA)
SSC, standard saline citrate
STAT, signal transducer and activator of transcription
SV40, simian virus 40
$t_{1/2}$, half-life, half-time
TAMRA, 5-(and 6)-carboxytetramethylrhodamine
TAP, transporter associated with Ag processing
Tat, terminal deoxynucleotidyltransferase
TBS, Tris-buffered saline
TBST, TBS with Tween 20
TCA, trichloroacetic acid
TCR, T cell receptor for Ag
TDP, thymidine 5′-diphosphate
TdT, terminal deoxynucleotidyltransferase
TGF, transforming growth factor
Th cell, T helper cell
TLC, thin layer chromatography
TLR, Toll-like receptor
TMP, thymidine 5′-monophosphate
TNF, tumor necrosis factor
TNP, trinitrophenyl
TRAIL, TNF-related apoptosis-inducing ligand
Tris, tris(hydroxymethyl)aminomethane
tRNA, transfer RNA
TTP, thymidine 5′-triphosphate
TUNEL, Tdt-mediated dUTP nick end labeling
U, unit (only with numbers)
UDP, uridine 5′-diphosphate
UMP, uridine 5′-monophosphate
UTP, uridine 5′-triphosphate
UV, ultraviolet
v/v, volume to volume ratio (%)
v/w, volume to weight ratio (%)
V region, variable region of Ig
VCAM, vascular cell adhesion molecule
V(D)J or VDJ, variable diversity joining
VLA, very late activation Ag
W, watt (only with numbers)
WBC, white blood cell
WEHI medium
wk, week (only with numbers)
xid, X-linked immunodeficiency
Zap70, ζ-associated protein 70 (or ζ-chain-associated protein 70)

Keywords

Animals
Human
Rodent
Other Animals

Cells
B Cells
Dendritic Cells
Endothelial Cells
Eosinophils
Mast Cells/Basophils
Monocytes/Macrophages
Natural Killer Cells
Neutrophils
Stem Cells
Stromal Cells
T Cells
T Cells, Cytotoxic
Th1/Th2 Cells

Diseases
Autoimmunity
Diabetes
EAE/MS
Endotoxin Shock
Graft Versus Host Disease
Immunodeficiency Diseases
Rheumatoid Arthritis
Systemic Lupus Erythematosus

Infections
AIDS
Bacterial
Fungal
Parasitic-Helminth
Parasitic-Protozoan
Viral

Molecules
Acute-Phase Reactants
Adhesion Molecules
Antibodies
Antigens/Peptides/Epitopes
Autoantibodies
Cell Surface Molecules
Chemokines
Complement
Cytokine Receptors
Cytokines
Fc Receptors
Lipid Mediators
Lipopolysaccharide
MHC
Nitric Oxide
Protein Kinases/Phosphatases
Superantigens
T Cell Receptors
Transcription Factors

Processes
Allergy
Antigen Presentation/Processing
Apoptosis
Cell Activation
Cell Differentiation
Cell Proliferation
Cell Trafficking
Chemotaxis
Comparative Immunology/Evolution
Costimulation
Cytotoxicity
Gene Rearrangement
Gene Regulation
Hematopoiesis
Inflammation
Memory
Neuroimmunology
Phagocytosis
Repertoire Development
Reproductive Immunology
Signal Transduction
Tolerance/Suppression/Anergy
Transplantation
Tumor Immunity
Vaccination

Techniques/Approaches
Gene Therapy
Molecular Biology
Transgenic/Knockout Mice

Tissues
Lung
Mucosa
Skin
Spleen and Lymph Nodes
Thymus



2019 ADVANCED COURSE IN IMMUNOLOGY

July 28–August 2, 2019 | Seaport World Trade Center | Boston, Massachusetts

Director: Wayne M. Yokoyama, M.D.
Washington University School of Medicine in St. Louis

Don't miss the premier course in immunology for research scientists!

This intensive course is directed toward advanced trainees and scientists who wish to expand or update their understanding of the field. Leading experts will present recent advances in the biology of the immune system and address its role in health and disease. This is not an introductory course; attendees will need to have a firm understanding of the principles of immunology.

Faculty

Ulrich H. von Andrian, *Harvard Medical School Ragon Institute of MGH, MIT, and Harvard*
Anatomy of the Immune Response

Jonathan C. Kagan, *Children's Hospital Boston Harvard Medical School*
Innate Immunity: Pattern Recognition and Anti-microbial Mechanisms

Kate A. Fitzgerald, *University of Massachusetts Medical School*
Innate Immunity: Gene Regulation

Wayne M. Yokoyama, *Washington University School of Medicine*
NK Cells—Their Receptors and Function in Health and Disease

Albert S. Bendelac, *University of Chicago*
Innate Immunity: Cellular Mechanisms

Bethany B. Moore, *University of Michigan*
Molecular and Cellular Mediators of Inflammation

Stephanie Eisenbarth, *Yale School of Medicine*
Dendritic Cells

Barry P. Sleckman, *Weill Cornell Medical College*
The Generation and Modification of Lymphocyte Antigen Receptor Genes

Lisa A. Borghesi, *University of Pittsburgh School of Medicine*
B Cell Development

Avery August, *Cornell University*
T Cell Development

Kai W. Wucherpfennig, *Dana-Farber Cancer Institute, Harvard Medical School*
MHC-restricted Antigen Presentation to T Cells

Morgan Huse, *Memorial Sloan Kettering Cancer Center*
Signaling from Antigen Receptors

Rachael A. Clark, *Brigham and Women's Hospital, Harvard Medical School*
T Cell Memory in Peripheral Tissues

Deepta Bhattacharya, *University of Arizona*
B Cell Memory

Brian A. Cobb, *Case Western Reserve University School of Medicine*
Glycoimmunology

Richard S. Blumberg, *Brigham and Women's Hospital, Harvard Medical School*
Mucosal Immunity

Cathryn Nagler, *University of Chicago*
Effect of the Microbiome on Immunity

Jennifer A. Philips, *Washington University School of Medicine*
Immune Response to Pathogens

Eric Meffre, *Yale University*
B Cell Tolerance and Autoimmunity

James J. Moon, *Harvard Medical School, Massachusetts General Hospital*
T Cell Tolerance and Autoimmunity

Jonathan Kipnis, *University of Virginia School of Medicine*
Neuroimmunology

Maxim N. Artyomov, *Washington University School of Medicine*
Single Cell RNA-seq Analysis

Dario Vignali, *University of Pittsburgh School of Medicine*
Tumor Immunology

Galit Alter, *Ragon Institute of MGH, MIT, and Harvard*
Vaccines

Lisa M. Olson, *AbbVie*
Immunotherapeutics

For complete course details and registration, visit www.aai.org/Education/Courses

For assistance, contact **(301) 634-7178** or **meetings@aai.org**. Overseas applicants are advised to apply early for visas; for details, see Visa Information at **www.aai.org/Education/Courses/Advanced**.